FDA
- Status: approved
🇺🇸 Hospital-Based Vaccination Pathway in United States
Hospital-Based Vaccination Pathway (hospital-based-vaccination-pathway) regulatory status in United States.
Marketing authorisation
Pricing & reimbursement
- annual_list: USD 80000.00 per year
Hospital-Based Vaccination Pathway in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in United States
Frequently asked questions
Is Hospital-Based Vaccination Pathway approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Hospital-Based Vaccination Pathway in United States?
Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.
What does Hospital-Based Vaccination Pathway cost in United States?
annual_list: USD 80000.00 per year. Final patient cost depends on reimbursement and any patient access scheme.